Sanofi: Qfitlia Approval A Bright Spot As Landscape Darkens For European Pharma
Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.
Health and Me on MSN4h
FDA Approves Qfitlia For Hemophilia Patients
The approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...
InsideNoVa7h
FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia
The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...
MPR1d
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
PharmExec2d
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
Pharmaceutical Technology on MSN2d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper hand.
Explore more
Medical Dialogues1d
FDA Approves fitusiran for Hemophilia A and B
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
PharmiWeb2d
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
BioSpace2d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
FDA Approves Sanofi's Hemophilia Drug
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Fierce Pharma5d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
BioPharma Dive5d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...